Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11623789 | 0.90 | HPGD (0.43) | HPGDHSD17B10KDM4ENPBWR1DGAT1 | |
| SCHEMBL11625133 | 0.83 | KIF11 (0.44) | HPGDHSD17B10KDM4ELMNAMAPK13 | |
| SCHEMBL26093883 | 0.83 | KDM4E (0.44) | HPGDHSD17B10KDM4ELMNAPOLB | |
| SCHEMBL8797359 | 0.83 | GFER (0.50) | HPGDKDM4ENPBWR1DGAT1KCNH2 | |
| SCHEMBL11626212 | 0.81 | KIF11 (0.42) | HPGDHSD17B10KDM4ELMNAPOLB | |
| SCHEMBL27731893 | 0.81 | NPBWR1 (0.44) | HPGDNPBWR1NISCHPTGS1SDHB | |
| SCHEMBL27731900 | 0.81 | KDM4E (0.45) | HPGDHSD17B10KDM4ELMNAMAPK13 | |
| SCHEMBL3468298 | 0.81 | HPGD (0.38) | HPGD | |
| SCHEMBL3095172 | 0.81 | HPGD (0.38) | HPGDKDM4EDGAT1KCNH2POLB | |
| SCHEMBL16661274 | 0.81 | KDM4E (0.45) | HPGDKDM4EDGAT1LMNAMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191449-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016037578-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-17 | — | — | WO | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2461688-A1 | PESTICIDAL COMPOSITIONS | Dow AgroSciences LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| WO-2011017513-A1 | PESTICIDAL COMPOSITIONS | DOW AGROSCIENCES LLC (US) | 2011-02-10 | — | — | WO | disclosed |
| CN-101239981-B | Pyrazolo and imidazo-pyrimidine derivatives | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
| CN-1153766-C | Nitroketone compound, its preparing process and pharmaceutical composition containing same | ɪά��ʵ���� | 2004-06-16 | — | — | CN | disclosed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-0967207-B1 | Nitrone derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-09-11 | — | — | EP | disclosed |
| CN-1245169-A | Nitroketone compound, its preparing process and pharmaceutical composition containing same | ADIR (FR) | 2000-02-23 | — | — | CN | disclosed |
| JP-2000026428-A | NEW NITRONE COMPOUND, ITS PRODUCTION AND MEDICAL COMPOSITION CONTAINING THE SAME | ADIR | 2000-01-25 | — | — | JP | disclosed |
| EP-0967207-A1 | Nitrone derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-12-29 | — | — | EP | disclosed |
| US-4125530-A | FROM 1,1-DIHALO-3,3,3-TRIFLUOROACETONE, BASE, AMMONIA AND A CARBOXALDEHYDE | MERCK & CO., INC. (US) | 1978-11-14 | — | — | US | disclosed |
| US-4032522-A | ANTI-GOUT, ANTI-HYPERURICEMIC | MERCK & CO., INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1I2 | HPGD 526/4885HSD17B10 477/4885KDM4E 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.